Parkinson’s Disease and Type 2 Diabetes Mellitus: Interrelated Pathogenetic Mechanisms and Common Therapeutic Approaches

被引：0
作者：
Troshneva A.Y. [1 ]
Ametov A.S. [1 ]
机构：
[1] Russian Medical Academy for Continuing Professional Education, Russian Ministry of Health, Moscow
来源：
Neuroscience and Behavioral Physiology | 2023年 / 53卷 / 6期
关键词：
diabetes mellitus; insulin resistance; neurodegeneration; Parkinson’s disease;
D O I：
10.1007/s11055-023-01488-4
中图分类号：
学科分类号：
摘要：
This review discusses the epidemiological, clinical, and pathophysiological aspects of the relationship between Parkinson’s disease (PD) and type 2 diabetes mellitus (DM2). DM2 increases the risk of developing PD and correlates with the rate of progression of PD and the severity of motor and cognitive deficits. At the same time, insulin resistance may operate as a key link in the pathogenesis of both diseases: peripherally in DM2 and in brain tissues in PD. In this regard, the use of antidiabetic drugs as neuroprotective agents opens up opportunities for developing a new targeted therapy strategy which modifies the course of PD. © 2023, Springer Nature Switzerland AG.
引用
收藏
页码：959 / 965
页数：6
相关论文
共 111 条
  • [1] Mhyre T.R., Boyd J.T., Hamill R.W., Maguire-Zeiss K.A., Parkinson’s disease, Subcell. Biochem., 65, pp. 389-455, (2012)
  • [2] Parkinson’s Disease Collaborators, “Global, regional, and national burden of Parkinson’s disease, 1990–2016: A systematic analysis for the Global Burden of Disease Study, Lancet Neurol, 17-20, pp. 939-953, (2016)
  • [3] Illarioshkin S.N., Current views on the etiology of Parkinson’s disease, Nevrol. Zh., 20, 4, pp. 4-13, (2015)
  • [4] Veryugina N.I., Levin O.S., Lyashenko E.A., Neuroendocrine and metabolic impairments in Parkinson’s disease, Zh. Nevrol. Psikhiatr., 120, 10-2, pp. 67-73, (2020)
  • [5] Hassan A., Sharma Kandel R., Et al., Diabetes mellitus and Parkinson’s disease: Shared pathophysiological links and possible therapeutic implications”, Cureus, 12, No., 8, (2020)
  • [6] Athauda D., Foltynie T., Insulin resistance and Parkinson’s disease: A new target for disease modification?, Prog. Neurobiol., 145-146, pp. 98-120, (2016)
  • [7] Aviles-Olmos I., Limousin P., Lees A., Foltynie T., Parkinson’s disease, insulin resistance and novel agents of neuroprotection, Brain, 136, 2, pp. 374-384, (2013)
  • [8] Santiago J.A., Potashkin J.A., Shared dysregulated pathways lead to Parkinson’s disease and diabetes, Trends Mol. Med., 9, pp. 176-186, (2013)
  • [9] Craft S., Watson G.S., Insulin and neurodegenerative disease: Shared and specific mechanisms, Lancet Neurol., 3, pp. 169-178, (2004)
  • [10] Biosa A., Outeiro T.F., Bubacco L., Bisaglia M., Diabetes mellitus as a risk factor for Parkinson’s disease: A molecular point of view, Mol. Neurobiol., 55, pp. 8754-8763, (2018)
12345678910